TABLE 3.
Setting 1: Measures of size of the trial across scenarios, total duration in weeks, and total number of patients
| TITE‐CRM | TITE‐CRM2 | ICSDP | POMM | nTTP | TITE‐BOIN | TITE‐mTPI2 | R‐mTPI2 | |
|---|---|---|---|---|---|---|---|---|
| Scenario | Mean duration in weeks (SD) | |||||||
| A | 39 (11) | 36 (10) | 46 (10) | 52 (9) | 32 (5) | 40 (14) | 46 (23) | 50 (26) |
| B | 55 (14) | 53 (15) | 55 (10) | 55 (8) | 44 (14) | 57 (13) | 81 (31) | 95 (34) |
| C | 34 (9) | 32 (7) | 44 (10) | 52 (9) | 31 (4) | 35 (16) | 37 (22) | 37 (23) |
| D | 63 (7) | 57 (8) | 57 (5) | 55 (6) | 56 (10) | 49 (3) | 85 (7) | 100 (9) |
| Mean | 48 | 45 | 51 | 53 | 41 | 45 | 62 | 70 |
| Scenario | Mean number of patients (SD) | |||||||
| A | 14 (6) | 12 (5) | 17 (5) | 20 (4) | 10 (2) | 19 (6) | 15 (5) | 15 (5) |
| B | 22 (7) | 21 (8) | 22 (5) | 22 (4) | 16 (7) | 26 (4) | 21 (6) | 23 (7) |
| C | 11 (4) | 10 (3) | 16 (5) | 20 (4) | 10 (2) | 17 (7) | 13 (5) | 12 (5) |
| D | 26 (4) | 23 (4) | 23 (3) | 22 (2) | 23 (5) | 24 (1) | 24 (2) | 25 (2) |
| Mean | 18 | 17 | 20 | 21 | 15 | 22 | 18 | 19 |